Dexrazoxane enhances efficacy of all- trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines

Leuk Lymphoma. 2021 Feb;62(2):473-477. doi: 10.1080/10428194.2020.1827245. Epub 2020 Oct 16.

Authors

Eric J Norris¹, Yogin C Patel¹, Kaitlin E Klotz¹, Nury Steuerwald², Wendell D Jones³, Jaroslaw P Maciejewski⁴, Ram N Ganapathi¹, Mahrukh K Ganapathi¹

Affiliations

¹ Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
² Molecular Biology and Genomics Core Facility, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
³ EA Genomics, Division of Q Solutions, Morrisville, NC, USA.
⁴ Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

PMID: 33064055
DOI: 10.1080/10428194.2020.1827245

No abstract available

Publication types

Letter

MeSH terms

Cell Differentiation
Cell Line
Dexrazoxane*
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Promyelocytic, Acute* / drug therapy
Tretinoin

Substances

Dexrazoxane
Tretinoin